{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:50:56Z","timestamp":1772747456196,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.ejim.2010.12.003","type":"journal-article","created":{"date-parts":[[2011,1,8]],"date-time":"2011-01-08T04:23:55Z","timestamp":1294460635000},"page":"249-253","source":"Crossref","is-referenced-by-count":22,"title":["The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients"],"prefix":"10.1016","volume":"22","author":[{"given":"Murat","family":"Koksal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Ali","family":"Eren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Nuri","family":"Turan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tevfik","family":"Sabuncu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2010.12.003_bb0005","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/er.2001-0039","article-title":"Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes","volume":"23","author":"Evans","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ejim.2010.12.003_bb0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2337\/diacare.14.9.839","article-title":"Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis","volume":"14","author":"Ginsberg","year":"1991","journal-title":"Diab Care"},{"issue":"5","key":"10.1016\/j.ejim.2010.12.003_bb0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1359-6101(03)00052-2","article-title":"Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha","volume":"14","author":"Ruan","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ejim.2010.12.003_bb0020","first-page":"1233","article-title":"Oxidant-antioxidant system: role and significance in human body","volume":"40","author":"Irshad","year":"2002","journal-title":"Indian J Exp Biol"},{"issue":"21","key":"10.1016\/j.ejim.2010.12.003_bb0025","first-page":"18","article-title":"Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?","volume":"109","author":"Sch\u00f6nbeck","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ejim.2010.12.003_bb0030","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11883-003-0008-z","article-title":"Isoprenoid metabolism and the pleiotropic effects of statins","volume":"5","author":"Laufs","year":"2003","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ejim.2010.12.003_bb0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.amjcard.2008.09.071","article-title":"A Review of the Current Status of the Management of Mixed Dyslipidemia Associated with Diabetes Mellitus and Metabolic Syndrome","volume":"102","author":"Davidson","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2010.12.003_bb0040","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/hq1101.098486","article-title":"Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors","volume":"21","author":"Takemoto","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.ejim.2010.12.003_bb0045","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00043798-200306000-00005","article-title":"Statins and oxidative stress during atherogenesis","volume":"10","author":"Norata","year":"2003","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.ejim.2010.12.003_bb0050","first-page":"181","article-title":"Statins decrease oxidative stress and ICD therapies","volume":"10","author":"Bloom","year":"2010","journal-title":"Cardiol Res Pract"},{"issue":"3","key":"10.1016\/j.ejim.2010.12.003_bb0055","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0002-9149(01)02226-3","article-title":"Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia","volume":"89","author":"Davidson","year":"2002","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.ejim.2010.12.003_bb0060","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1067\/mhj.2002.128049","article-title":"Effects of rosuvastatin and atorvastatin compared over 52weeks of treatment in patients with hypercholesterolemia","volume":"144","author":"Olsson","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2010.12.003_bb0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1745-6215-7-35","article-title":"Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia\u2014prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)","volume":"7","author":"Clearfield","year":"2006","journal-title":"Trials"},{"key":"10.1016\/j.ejim.2010.12.003_bb0070","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.amjcard.2007.05.044","article-title":"Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined c-reactive protein (<2mg\/L) and low-density lipoprotein cholesterol (<70mg\/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study)","volume":"100","author":"Betteridge","year":"2007","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2010.12.003_bb0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2008.03.057","article-title":"Comparison effect of atorvastatin (10 versus 80mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome","volume":"102","author":"Singh","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2010.12.003_bb0080","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.jacc.2008.01.026","article-title":"The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans","volume":"51","author":"Ky","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2010.12.003_bb0085","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejphar.2007.04.065","article-title":"Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus","volume":"569","author":"Riad","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.ejim.2010.12.003_bb0090","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/0267659109350240","article-title":"Effect of preoperative atorvastatin therapy on paraoxonase activity and oxidative stress after coronary artery bypass grafting","volume":"24","author":"Kurban","year":"2009","journal-title":"Perfusion"},{"key":"10.1016\/j.ejim.2010.12.003_bb0095","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.atherosclerosis.2007.11.016","article-title":"Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis","volume":"199","author":"Schupp","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2010.12.003_bb0100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.amjcard.2004.03.052","article-title":"Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia","volume":"94","author":"Lu","year":"2004","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2010.12.003_bb0105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2125.2005.02568.x","article-title":"Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy","volume":"61","author":"Resch","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.ejim.2010.12.003_bb0110","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.clinbiochem.2005.08.008","article-title":"A new automated colorimetric method for measuring total oxidant status","volume":"38","author":"Erel","year":"2005","journal-title":"Clin Biochem"},{"issue":"4","key":"10.1016\/j.ejim.2010.12.003_bb0115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clinbiochem.2003.11.015","article-title":"A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation","volume":"37","author":"Erel","year":"2004","journal-title":"Clin Biochem"},{"issue":"1","key":"10.1016\/j.ejim.2010.12.003_bb0120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ab.2003.10.022","article-title":"Plasma lipid hydroperoxides measurement by an automated xylenol orange method","volume":"325","author":"Arab","year":"2004","journal-title":"Anal Biochem"},{"key":"10.1016\/j.ejim.2010.12.003_bb0125","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.HYP.37.4.1053","article-title":"Diabetes, hypertension, and cardiovascular disease : an update","volume":"37","author":"Sowers","year":"2001","journal-title":"Hypertension"},{"issue":"7134","key":"10.1016\/j.ejim.2010.12.003_bb0130","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","article-title":"Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)","volume":"316","author":"Turner","year":"1998","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ejim.2010.12.003_bb0135","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2010.12.003_bb0140","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1172\/JCI0216421","article-title":"Isoprenoids as mediators of the biological effects of statins","volume":"110","author":"Liao","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejim.2010.12.003_bb0145","first-page":"4","article-title":"URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study","volume":"3","author":"Berne","year":"2005","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.ejim.2010.12.003_bb0150","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ahj.2003.10.004","article-title":"Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study","volume":"147","author":"Schuster","year":"2004","journal-title":"Am Heart J"},{"issue":"33","key":"10.1016\/j.ejim.2010.12.003_bb0155","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.3748\/wjg.15.4137","article-title":"Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress","volume":"15","author":"Kawahito","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.ejim.2010.12.003_bb0160","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/dmrr.196","article-title":"The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society","volume":"17","author":"R\u00f6sen","year":"2001","journal-title":"Diab Metab Res Rev"},{"issue":"11","key":"10.1016\/j.ejim.2010.12.003_bb0165","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1681\/ASN.2006080895","article-title":"Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production","volume":"18","author":"Prabhakar","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.ejim.2010.12.003_bb0170","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/db08-0057","article-title":"Oxidative stress as a major culprit in kidney disease in diabetes","volume":"57","author":"Forbes","year":"2008","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.ejim.2010.12.003_bb0175","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11154-008-9090-4","article-title":"Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives","volume":"9","author":"Madsen-Bouterse","year":"2008","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"10.1016\/j.ejim.2010.12.003_bb0180","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/bjo.2007.130542","article-title":"The change of oxidative stress products in diabetes mellitus and diabetic retinopathy","volume":"92","author":"Pan","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ejim.2010.12.003_bb0185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/B:REMD.0000032411.11422.e0","article-title":"New insights into the mechanisms of diabetic neuropathy","volume":"5","author":"Vincent","year":"2004","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"10.1016\/j.ejim.2010.12.003_bb0190","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF00400231","article-title":"Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats","volume":"36","author":"Cameron","year":"1993","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ejim.2010.12.003_bb0195","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/vhrm.1.1.55.58939","article-title":"Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium","volume":"1","author":"Ding","year":"2005","journal-title":"Vasc Health Risk Manage"},{"issue":"3","key":"10.1016\/j.ejim.2010.12.003_bb0200","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1373\/clinchem.2005.060194","article-title":"Increased plasma markers of oxidative stress are associated with coronary heart disease in males with diabetes mellitus and with 10-year risk in a prospective sample of males","volume":"52","author":"Stephens","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejim.2010.12.003_bb0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1475-2840-7-29","article-title":"The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes","volume":"7","author":"Meerwaldt","year":"2008","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ejim.2010.12.003_bb0210","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diabres.2007.01.036","article-title":"Role of vascular reactive oxygen species in development of vascular abnormalities in diabetes","volume":"77","author":"Son","year":"2007","journal-title":"Diab Res Clin Pract"},{"issue":"10","key":"10.1016\/j.ejim.2010.12.003_bb0215","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2337\/diacare.20.10.1589","article-title":"Total plasma antioxidant capacity predicts thrombosis-prone status in NIDDM patients","volume":"20","author":"Ceriello","year":"1997","journal-title":"Diab Care"},{"issue":"6","key":"10.1016\/j.ejim.2010.12.003_bb0220","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1046\/j.1365-2362.1997.1390687.x","article-title":"Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus","volume":"27","author":"Maxwell","year":"1997","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"10.1016\/j.ejim.2010.12.003_bb0225","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.lfs.2007.04.027","article-title":"Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine","volume":"81","author":"Bolayirli","year":"2007","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.ejim.2010.12.003_bb0230","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.atherosclerosis.2007.10.003","article-title":"Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus","volume":"198","author":"Wenzel","year":"2008","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.ejim.2010.12.003_bb0235","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/1074248406295523","article-title":"Effect of atorvastatin on type 2 diabetic dyslipidemia","volume":"11","author":"Save","year":"2006","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"5\u20136","key":"10.1016\/j.ejim.2010.12.003_bb0240","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1440-1681.2007.04853.x","article-title":"In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin","volume":"35","author":"Ajith","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"2","key":"10.1016\/j.ejim.2010.12.003_bb0245","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/01.fjc.0000167010.98177.78","article-title":"Rosuvastatin treatment protects against nitrate-induced oxidative stress","volume":"46","author":"Otto","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"issue":"12","key":"10.1016\/j.ejim.2010.12.003_bb0250","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1157\/13113929","article-title":"Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia","volume":"60","author":"G\u00f3mez-Garc\u00eda","year":"2007","journal-title":"Rev Esp Cardiol"},{"issue":"4","key":"10.1016\/j.ejim.2010.12.003_bb0255","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s11095-008-9798-6","article-title":"Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia","volume":"26","author":"Qu","year":"2009","journal-title":"Pharm Res"},{"issue":"9","key":"10.1016\/j.ejim.2010.12.003_bb0260","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00125-008-1060-6","article-title":"The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation","volume":"51","author":"Calkin","year":"2008","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ejim.2010.12.003_bb0265","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0021-9150(02)00063-1","article-title":"Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes","volume":"164","author":"Fuhrman","year":"2002","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.ejim.2010.12.003_bb0270","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S1734-1140(09)70146-X","article-title":"Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status","volume":"61","author":"Nagila","year":"2009","journal-title":"Pharmacol Rep"},{"issue":"1","key":"10.1016\/j.ejim.2010.12.003_bb0275","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00019501-200202000-00009","article-title":"The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status","volume":"13","author":"Orem","year":"2002","journal-title":"Coron Artery Dis"},{"issue":"4","key":"10.1016\/j.ejim.2010.12.003_bb0280","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1540-8191.2008.00600.x","article-title":"Atorvastatin increases myocardial indices of oxidative stress in a porcine model of hypercholesterolemia and chronic ischemia","volume":"23","author":"Sodha","year":"2008","journal-title":"J Card Surg"},{"issue":"1\u20134","key":"10.1016\/j.ejim.2010.12.003_bb0285","first-page":"61","article-title":"Effects of atorvastatin on some inflammatory parameters in severe primary hypercholesterolemia","volume":"40","author":"Dobreanu","year":"2002","journal-title":"Rom J Intern Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620510002396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620510002396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T12:52:05Z","timestamp":1544014325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620510002396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0953620510002396"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2010.12.003","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}